Skip to main
CI
CI logo

Cigna (CI) Stock Forecast & Price Target

Cigna (CI) Analyst Ratings

Based on 18 analyst ratings
Buy
Strong Buy 33%
Buy 56%
Hold 11%
Sell 0%
Strong Sell 0%

Bulls say

Cigna Group is strategically positioned to leverage the anticipated $100 billion biosimilar market by 2030, underscoring its growth potential within the pharmaceutical landscape. Additionally, the company's recent capability to generate double-digit savings on GLP-1 therapies for employer clients showcases its focus on delivering cost-effective solutions, strengthening its value proposition in the health insurance sector. Furthermore, the expansion of Evernorth is expected to enhance Cigna's resilience against economic downturns, as its end markets demonstrate greater stability, thus supporting the company’s overall financial stability and growth trajectory.

Bears say

Cigna Group faces significant risks that contribute to a negative outlook, including challenges in accurately pricing and managing healthcare costs, which could undermine profitability. Regulatory scrutiny on pharmacy benefit managers (PBMs) is expected to persist longer than anticipated, potentially impacting Cigna’s operational stability and market position. Additionally, slow adoption of biosimilars and specialty drugs, coupled with potential client losses in the Evernorth segment, could further hinder growth prospects and threaten the retention of commercial membership, particularly amid rising unemployment rates.

Cigna (CI) has been analyzed by 18 analysts, with a consensus rating of Buy. 33% of analysts recommend a Strong Buy, 56% recommend Buy, 11% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Cigna and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Cigna (CI) Forecast

Analysts have given Cigna (CI) a Buy based on their latest research and market trends.

According to 18 analysts, Cigna (CI) has a Buy consensus rating as of Nov 26, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $359.72, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $359.72, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Cigna (CI)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.